Pediatric monoclonal antibody (PedMAb)

Phase I study to determine Safety and Pharmacokinetics of subcutaneous administration of potent and broadly neutralizing anti-HIV-1 monoclonal antibodies (bNAbs), given to HIV-1 exposed and uninfected (HEU) neonates and infants (PedMAb1)

PedMAb1 is being conducted as a partnership between the SAMRC, IRCCS Ospedale San Raffaele, Milan, Italy, University of Montpellier, France, Wits Health Consortium and University of Bergen, Norway, with funding from EDCTP and the SAMRC

Read More

Objectives

To evaluate the safety (Adverse Events = AE)

until day 28 after a single subcutaneous (SC) administration of one bNAb, tested at increasing doses within 96 hours of birth, in breastfeeding HIV exposed uninfected (HEU) neonates (arms 1 through 5)
 

Read More

until day 28 after two single SC administration of two bNAbs, tested at increasing doses within 96 hours of birth, in breastfeeding HEU neonates (arm 6)
 

Read More

until day 28 after two single SC administrations of two bNAbs, within 96 hours of birth and repeated at 3 months in breastfeeding HEU neonates (arm 6b)

Read More

Where is the study conducted? 

The study is being conducted in South Africa only. It is conducted at the SAMRC (South African Medical Research Council), HIDRU (HIV and other Infectious Diseases Research Unit) - Chatsworth Clinic Research Site (CRS) which is located on the grounds of the RK Khan Hospital, eThekwini district, KwaZulu-Natal